Sanofi Could Be Top By 2012

Stephanie Sutton Pharm Tech EuropeWith 2011 sales of approximately $54.1 billion, Pfizer currently holds the crown as the world’s largest drugmaker, but next year may see the pharma giant usurped from its throne by Sanofi and Novartis, who will claim pole and second position respectively in the global pharmaceutical rankings. Pfizer, meanwhile, will drop to third place, and is likely to remain there for the foreseeable future, according to analysis firm EvaluatePharma. Read more »

New Hope for Neglected Diseases

Erik Greb PharmTech editorIt’s getting harder for the pharmaceutical industry to ignore neglected diseases. The globalization of national economies and the rise in air travel are increasing the potential for exposure to these diseases, which previously had been limited to the developing world. “Now is the time to have this discussion,” Kishor M. Wasan, chair-elect of the American Association of Pharmaceutical Scientists’s Pharmaceuticals in Global Health Focus Group, told Pharmaceutical Technology earlier this month. Industry now seems to be getting the message. Read more »

Could Wild Gudgeon Be Canaries in a Coal Mine?

Erik Greb PharmTech editor

Concern about pharmaceuticals in our water supply has been in the public consciousness for a few years now. In 2009, the Environmental Protection Agency found traces of various drugs in fish caught in rivers that receive effluent from wastewater-treatment plants. The drugs were believed to come from doses that people had excreted or flushed down the toilet. In response, FDA updated its guidelines for disposing of drugs. New research, however, shows another potential source of drugs in our waterways. Read more »

A Call for Clarity about Vaccines

Erik Greb PharmTech editorAs I wrote last week, the market for vaccines is expanding, and the newswires have stories about these products almost daily. Sanofi and GlaxoSmithKline, to name just two major players, are increasing investments in research and manufacturing capacity for these therapies. Kalorama Information predicts that sales of pediatric vaccines will grow even more quickly than sales for adult vaccines. Yet drugmakers have surely noticed that not all publicity about vaccines has been positive. Read more »

Bayer and “the Fairer Sex”

Erik Greb PharmTech editorHaven’t we heard this story before? Bayer HealthCare Pharmaceuticals faces a class action suit alleging that it discriminates against its female employees. In late May, the class bringing the suit expanded to include female sales representatives and all women in the company’s Consumer Care unit. The employees’ complaint alleges that Bayer is hostile toward women, pays them less than it pays men, and retaliates against women who object to these conditions. Read more »

Diligence Is Our Due

Erik Greb PharmTech editorIn 2010, the US House of Representatives’s Committee on Oversight and Government Reform held two hearings after scandalous cGMP violations at McNeil’s Puerto Rico facilities came to light. Former FDA Deputy Commissioner Joshua Sharfstein told the Committee that the agency would review McNeil’s plan for correcting deficiencies to ensure that the corrective actions were effective. “FDA intends to keep a close eye on these facilities until the company earns our confidence back,” said Sharfstein. Read more »

Big Pharma, We Hardly Knew Ye

Erik Greb PharmTech editorBig Pharma’s sales forecast is not likely to improve anytime soon. Consulting firm Bain and Company predicts that the top 25 drug companies’ annual sales growth will be no more than 1% through 2016. To compensate for reduced revenue, investors are urging manufacturers to cut expenses that do not add value. One such expense, in many investors’ eyes, is research and development (R&D). Read more »

A Prescription for New Jersey, and for the Drug Industry

Erik Greb PharmTech editorMention New Jersey to someone on the street, and he or she is likely to think of Springsteen, the Sopranos, or (God forbid) Snooki. But PharmTech readers know that New Jersey is an important state for the drug industry. Many big companies, such as Johnson and Johnson, sanofi-aventis, Novartis, and Pfizer, have headquarters or other offices in the state. And the Garden State’s drugmakers are facing the same difficulties that confront the industry at large. Read more »

Sanofi Aventis to Acquire Genzyme for $20.1 Billion

Alexis Brekke Pellek PharmTech editorSanofi aventis and Genzyme have finally agreed on a deal for Sanofi’s acquisition of the Cambridge, MA-based biotechnology company. The agreement values Genzyme at roughly $20.1 billion, or $74 per share, according to a joint statement by the companies. Read more »

Will the Vise Tighten on Pay-for-Delay Agreements?

Erik Greb PharmTech editorThe Federal Trade Commission opposes them. Lawmakers have tried and failed to abolish them. Soon, the US Supreme Court may rule on their legality. The future of pay-for-delay agreements, which pharmaceutical companies use to postpone the introduction of generic drugs to the market, could hang in the balance. Read more »

Next Page »